1.0The Medical Xchangehttps://themedicalxchange.com/en/Upward PCSK9 Inhibitor Dose Titration Uncommonly Required to Reach Goal in Challenging Patients - The Medical Xchangerich600338<blockquote class="wp-embedded-content" data-secret="khL2IOgeSM"><a href="https://themedicalxchange.com/en/2016/11/30/american-heart-association-scientific-sessions-201/">Upward PCSK9 Inhibitor Dose Titration Uncommonly Required to Reach Goal in Challenging Patients</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://themedicalxchange.com/en/2016/11/30/american-heart-association-scientific-sessions-201/embed/#?secret=khL2IOgeSM" width="600" height="338" title="“Upward PCSK9 Inhibitor Dose Titration Uncommonly Required to Reach Goal in Challenging Patients” — The Medical Xchange" data-secret="khL2IOgeSM" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://themedicalxchange.com/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
https://themedicalxchange.com/wp-content/uploads/2016/11/2363_AHA_2016_EN_Fig1.PNG960720New Orleans – When treated with a PCSK9 inhibitor, nearly 60% of patients with familial hypercholesterolemia (FH) achieve adequate and sustained control of low-density lipoprotein cholesterol (LDL-C) at the starting dose, according to an analysis of open-label study. The efficacy of the initial dose in this high-risk population, considered one of the most challenging, was drawn from a real-world extension study presented at the 2016 AHA Scientific Sessions. In the context of other PCSK9 data presented at the AHA regarding safety as well as the effects of these agents on lipids other than LDL-C, the FH study underscores that the role of PCSK9 inhibitors is controlling LDL-C in patients inadequately managed on statins alone.